Similar ABT-737-enhancing effects have also been reported upon Mcl1 inhibition in retinoblastoma- [108], melanoma- [109], breast-, prostate-, colon- [110] and liver- cancer cells [111]. This evidence concerns the gene MCL1 and melanoma.